Covid-19 Medications Acting as a Bridge to Vaccines
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, has said that monoclonal antibodies able to stop covid-19 from spreading, among other treatments, are working effectively as “a bridge” to the vaccine.
So much effort has been put into antibody-based medications that focus on using the blood products from patients that have recovered from Covid-19, as well as antivirals. Remdesivir and dexamethasone are both experimental drugs we have covered on this blog, and Fauci says the goal of using these treatments is to prevent patients from developing serious lung damage. He said to the Journal of the American Medical Association in an interview, “We are focusing very heavily now on treatment of early infection and, or prevention of infection. And that’s the bridge to the vaccine.”
Fauci believes that immunization of Covid-19 among Americans will not be prevalent until at least the third quarter of 2021, and with no vaccines definitively able to prevent Covid-19, companies are still rushing to develop treatments. Robert Schooley, a professor of medicine at the University of California, San Diego said, “Optimally, we’d have an oral antiviral drug you can give to more people earlier in the course of the illness. Which is better than nothing, but we’re still going to have to rely on drugs and behavioral modifications for a long time to come.”
New strategies are being researched regarding interferons which we posted in a previous blog. There is also research on infusions of coronavirus-neutralizing antibodies. Studies and trials are ongoing for these treatments and are showing hopeful signs. “We have some cautious optimism that monoclonal antibodies may be an important therapeutic for early disease,” Fauci said. “We need something to keep people out of the hospital.”
Be sure to check back frequently at the ABN Blog for updates